FDA approves first cell therapy for type 1 diabetes bit.ly/3CZU6Ie
Nature Reviews Drug Discovery
4,113 posts
Nature Reviews Drug Discovery
@NatRevDrugDisc
Editorial team of Nature Reviews Drug Discovery.
- Today's Nobel Prize for Physiology or Medicine relates to research on regulatory T cells nobelprize.org/prizes/medicin… For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review nature.com/articles/s4157… rdcu.be/eJHU8
- Yesterday, the FDA approved the first drug for schizophrenia with a new mechanism of action for more than half a century. For more on this mechanism - targeting muscarinic acetylcholine receptors - here's a recent review tinyurl.com/mwpahd99 rdcu.be/dVhpp
- FDA approves first schizophrenia drug with a new mechanism of action since the 1950s tinyurl.com/34ceshw4 Karuna/Bristol Myers Squibb’s KarXT (Cobenfy), which acts on M1/M4 muscarinic acetylcholine receptors, expands the treatment landscape beyond dopamine-targeted drugs
- The FDA has approved the first telomerase inhibitor, imetelstat, to treat myelodysplastic syndromes following an epic journey for the drug, which has been tested in more than 20 trials over the past 20 years in various cancers. Find out more here bit.ly/4ekijKL
- For readers interested in mRNA vaccines for infectious diseases, including the discoveries that have been recognized in the #NobelPrize2023, here's a comprehensive review bit.ly/3PMme7M
- The 2021 Nobel Prize in Physiology or Medicine has been awarded to David Julius and Ardem Patapoutian for discoveries of receptors for temperature and touch, such as TRPV1 bit.ly/3uEK1eF Find out about drug discovery targeting TRP channels here rdcu.be/cyLfq
- Targeting neutrophils for cancer therapy nature.com/articles/s4157… Neutrophils are abundant in the tumour microenvironment and often correlate with poor prognosis. This new Review discusses neutrophil subtypes, mechanisms influencing tumour progression and therapeutic targets
- Novel strategies to manage CAR-T cell toxicity tinyurl.com/ye3c94na This new Review discusses management of safety issues for CAR-T cell therapies such as cytokine release syndrome, as well as druggable targets and cellular engineering strategies to develop safer CAR-T cells
- The expanding role for small molecules in immuno-oncology go.nature.com/3KkW9JT A new review covering small molecules targeting cancer metabolism, cytokine/chemokine and innate immune pathways and T cell checkpoints that could be complementary to PD1/PDL1 inhibitors
- For anyone interested in where new drugs come from, here's a comprehensive analysis - it's not new, but it's still relevant rdcu.be/bkbwr
- For readers interested in CAR-T cell therapies in cancer immunotherapy, this Review in the May issue discusses management of toxicities and reviews druggable targets and cellular engineering strategies to develop safer CAR-T cells nature.com/articles/s4157… rdcu.be/em0rW
- For readers interested in approaches to reset the immune system to treat autoimmune diseases, here's a comprehensive review nature.com/articles/s4157… rdcu.be/elE4L
- For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms rdcu.be/eLS8A nature.com/articles/s4157…
